The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Panel members had questions about whether a new FDA proposal to require randomized trials for vaccines in healthy adults ...

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...

The FDA’s recent activities regarding Covid-19 vaccines stray far from the well-established standards of vaccine regulatory processes.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Government advisers are split on whether drugmakers should update their COVID-19 vaccines to better protect Americans this ...

Additionally, the Department of Health and Human Services unveiled the framework for the Most Favored Nation drug pricing ...